Neurobiological mechanisms in the kynurenine pathway and major depressive disorder
Author:
Bertollo Amanda Gollo1ORCID, Mingoti Maiqueli Eduarda Dama1ORCID, Ignácio Zuleide Maria1ORCID
Affiliation:
1. Laboratory of Physiology, Pharmacology and Psychopathology, Graduate Program in Biomedical Sciences , Federal University of Fronteira Sul , Chapecó , SC , Brazil
Abstract
Abstract
Major depressive disorder (MDD) is a prevalent psychiatric disorder that has damage to people’s quality of life. Tryptophan is the precursor to serotonin, a critical neurotransmitter in mood modulation. In mammals, most free tryptophan is degraded by the kynurenine pathway (KP), resulting in a range of metabolites involved in inflammation, immune response, and neurotransmission. The imbalance between quinolinic acid (QA), a toxic metabolite, and kynurenic acid (KynA), a protective metabolite, is a relevant phenomenon involved in the pathophysiology of MDD. Proinflammatory cytokines increase the activity of the enzyme indoleamine 2,3-dioxygenase (IDO), leading to the degradation of tryptophan in the KP and an increase in the release of QA. IDO activates proinflammatory genes, potentiating neuroinflammation and deregulating other physiological mechanisms related to chronic stress and MDD. This review highlights the physiological mechanisms involved with stress and MDD, which are underlying an imbalance of the KP and discuss potential therapeutic targets.
Publisher
Walter de Gruyter GmbH
Reference150 articles.
1. Agudelo, L.Z., Femenía, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, J.C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., et al.. (2014). Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159: 33–45, https://doi.org/10.1016/j.cell.2014.07.051. 2. Allen, A.P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., Scott, L., McLoughlin, D.M., Cryan, J.F., Dinan, T.G., et al.. (2015). Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J. Affect. Disord. 186: 306–311, https://doi.org/10.1016/j.jad.2015.06.033. 3. Alonso-Lana, S., Marquié, M., Ruiz, A., and Boada, M. (2020). Cognitive and neuropsychiatric manifestations of COVID-19 and effects on elderly individuals with dementia. Front. Aging Neurosci. 12: 588872, https://doi.org/10.3389/fnagi.2020.588872. 4. Banerjee, J., Alkondon, M., Pereira, E.F.R., and Albuquerque, E.X. (2012). Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J. Pharmacol. Exp. Ther. 341: 500–509, https://doi.org/10.1124/jpet.111.189860. 5. Bay-Richter, C., Linderholm, K.R., Lim, C.K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G.J., Erhardt, S., and Brundin, L. (2015). A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain. Behav. Immun. 43: 110–117, https://doi.org/10.1016/j.bbi.2014.07.012.
|
|